GILD Articles, Gilead Sciences Inc. - From 02/12/24

Gilead Sciences (NASDAQ:GILD) has announced an acquisition of CymaBay Therapeutics (NASDAQ:CBAY) that is expected to be completed in Q1 of 2024. Un...

Gilead Sciences Inc (NASDAQ:GILD) agreed to acquire CymaBay Therapeutics Inc (NASDAQ:CBAY) for $32.50 per share in cash or a to...

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, whic...

Gilead Sciences, Inc. (NASDAQ:GILD) shares are trading lower in Tuesday’s after-hours session after the company reported weak earnings result...

Arcus Biosciences Inc (NASDAQ:RCUS) shares are trading higher after Gilead Sciences Inc (NASDAQ:GILD) amended their collaboration ag...

HOOKIPA Pharma Inc (NASDAQ:HOOK) will focus its resources on prioritizing the clinical development of a randomized trial for its HB-200 progra...

Tuesday, the FDA announced to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the ...

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 5.49% on an annualized basis producing an average annual return...

In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell ca...

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.27% to 37...